Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma

The amount of infused CD34 + cells has been reported to be the strongest predictor of platelet recovery after autologous stem cell transplantation (ASCT). However, the timing of platelet recovery varies widely among patients even after the infusion of similar amounts of CD34 + cells. Therefore, we r...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2020-12, Vol.99 (12), p.2893-2901
Main Authors: Nagayama, Takashi, Ashizawa, Masahiro, Ikeda, Takashi, Kawaguchi, Shin-ichiro, Toda, Yumiko, Ito, Shoko, Ochi, Shin-ichi, Mashima, Kiyomi, Umino, Kento, Minakata, Daisuke, Nakano, Hirofumi, Yamasaki, Ryoko, Morita, Kaoru, Kawasaki, Yasufumi, Yamamoto, Chihiro, Fujiwara, Shin-ichiro, Hatano, Kaoru, Sato, Kazuya, Oh, Iekuni, Ohmine, Ken, Muroi, Kazuo, Kanda, Yoshinobu
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Blood Platelets - physiology
Body temperature
Cohort Studies
Female
Hematology
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic Stem Cell Transplantation - trends
Humans
Lymphoma
Lymphoma - blood
Lymphoma - therapy
Male
Medicine
Medicine & Public Health
Middle Aged
Multiple myeloma
Multiple Myeloma - blood
Multiple Myeloma - therapy
Oncology
Original Article
Predictive Value of Tests
Recovery (Medical)
Recovery of Function - physiology
Retrospective Studies
Stem cell transplantation
Stem cells
Transplantation, Autologous - methods
Transplantation, Autologous - trends
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The amount of infused CD34 + cells has been reported to be the strongest predictor of platelet recovery after autologous stem cell transplantation (ASCT). However, the timing of platelet recovery varies widely among patients even after the infusion of similar amounts of CD34 + cells. Therefore, we retrospectively assessed 99 patients who underwent their first ASCT for lymphoma or myeloma at our center. Thirteen patients (13%) did not achieve platelet engraftment, defined as a platelet count of at least 2.0 × 10 4 /μL without transfusion, at day 28 after transplantation, whereas 58 of 60 patients (97%) who received at least 2.0 × 10 6 /kg CD34 + cells achieved platelet engraftment within 28 days. Multivariate analysis identified the following significant risk factors for delayed platelet recovery: hemoglobin level and platelet count before stem cell harvest, body temperature of > 39 °C within 5 days after ASCT, and infusion of a small amount (
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-020-04112-4